CLIN Clinigen Group Plc

TIDMCLIN

RNS Number : 2755R

Clinigen Group plc

20 September 2017

20 September 2017

Rule 2.9 Announcement

In accordance with Rule 2.9 of the City Code on Takeovers and Mergers, Clinigen Group plc (the "Company") confirms that, as at the date of this announcement, its issued share capital consists of 115,165,344 ordinary shares 0.1 pence each with International Securities Identification Number GB00B89J2419. The Company holds no shares in treasury.

-Ends-

Contact details

 
 Clinigen Group plc                  Tel: +44 (0) 1283 
                                      495010 
 Shaun Chilton, Group Chief 
  Executive Officer 
 Martin Abell, Group Chief 
  Financial Officer 
 
 Numis Securities Limited            Tel: +44 (0) 20 
                                      7260 1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
  James Black / Tom Ballard 
  (Corporate Broking) 
 
 RBC Capital Markets - Joint         Tel: +44 (0) 20 
  Broker                              7653 4000 
 Marcus Jackson / Elliot Thomas 
  / Jack Wood 
 
 Instinctif Partners                 Tel: +44 (0) 20 
                                      7457 2020 
 Adrian Duffield / Melanie 
  Toyne-Sewell / Alex Shaw           Email: clinigen@instinctif.com 
 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

For more information, please visit www.clinigengroup.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RTTEANNEAESXEEF

(END) Dow Jones Newswires

September 20, 2017 05:07 ET (09:07 GMT)

Clinigen (LSE:CLIN)
Historical Stock Chart
From Jun 2024 to Jul 2024

Clinigen (LSE:CLIN)
Historical Stock Chart
From Jul 2023 to Jul 2024